1. FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug — Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 — Novo Nordisk's Ozempic wins FDA label boost with CV indication — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice


Discussion in 'Gensco Laboratories' started by anonymous, Aug 12, 2015 at 5:24 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Shady shady shady. Reps are nice but the people running this company are incompetent scum, to put it nicely. Just research the name of the pres on google, and the run in with the FDA. Enough said.